A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-Cell Lymphoma.

Closed

Abbreviated Title

Randomized Ph II of myeloablative vs. non-myeloablative consolidation in CNS b-cell lymphoma

Activated

07/01/2012

Closed

05/02/2017

Participants

CTSU

Research committees

Lymphoma

Treatment

Etoposide Filgrastim GM-CSF Leucovorin + 5-FU Methotrexate Rituximab Temozolomide Thiotepa Carmustine Cytarabine

Eligibility Criteria Expand/Collapse

SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Other Clinical Trials

SWOG Clinical Trial Number

CTSU/EA4232

A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

Research Committee(s)

Lymphoma

Activated

01/30/2025

Open

Phase

SWOG Clinical Trial Number

S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

Research Committee(s)

Lymphoma

Activated

08/01/2024

Accrual

37%

Open

Phase

SWOG Clinical Trial Number

S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma

Research Committee(s)

Lymphoma

Activated

06/30/2023

Accrual

14%

Open

Phase